Cyclosporin and serum lipids in renal transplant recipients

The Lancet

Volumn 341, Issue 8847, 1993, Pages 765-767

  Kronenberg, Florian ^a   König, Paul ^a   Lhotta, Karl ^a   Königsrainer, Alfred ^a   Sandholzer, Christoph ^a   Utermann, Gerd ^a   Dieplinger, Hans ^a   Hilbrands, L B ^b   Demacker, P N M ^b   Hoitsma, A J ^b   Irish, Ashley ^c   Segarra, A ^d   Chacon P ^d   Vilardell, M ^d   Piera, L L ^d   Webb, A T ^e   Brown, E A ^e  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; LIPID; PREDNISOLONE; TRIACYLGLYCEROL; LIPOPROTEIN A; PREDNISONE;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; KIDNEY TRANSPLANTATION; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SERUM; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; NOTE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; LONGITUDINAL STUDY;

AZATHIOPRINE; COMPARATIVE STUDY; CYCLOSPORINE; DRUG THERAPY, COMBINATION; HUMAN; KIDNEY TRANSPLANTATION; LIPIDS; LIPOPROTEIN(A); PREDNISONE; PROSPECTIVE STUDIES; LONGITUDINAL STUDIES;

EID: 0027478997     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(93)90546-S     Document Type: Letter

References (19)

1. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism
2. A study of the use of polyethylene glycol in estimating cholesterol in high density lipoprotein
3. Immunonephelometric assay of human apolipoprotein Al
4. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma
5. The prevalence of hyperlipidemia in renal transplant recipients
6. Cyclosporin A does not cause hyperlipidaemia in kidney graft recipients
7. Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation
8. Apolipoprotein(a) concentration decreases following renal transplantation
9. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism
10. Lipoprotein(a)in patients with proteinuria
11. Effects of cyclosporin A on LDL-receptor activity and the bile acid synthesis in hepatocyte monolayer activity and the bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat
12. Lipid abnormalities in renal transplant recipients treated with cyclosporine
13. Hyperlipidemia in stable renal transplant recipients
14. Cyclosporin A does not cause hyperlipidemia in kidney graft recipients
15. Effects of cyclosporin therapy on plasma lipoprotein levels
16. Effects of cyclosporin therapy on plasma lipoprotein levels
17. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism
18. High serum lipoprotein(a) concentrations in uraemic patients treated with continuous peritoneal dialysis
19. Proleinuria after renal transplantation